Navigation Links
Producing Vaccines from genetically modified crops

The consortium, called Pharma-Planta, wants to produce vaccines and other treatments for major //diseases, such as HIV/Aids, rabies and TB and they hope to start clinical trials by the year 2009. The project's aim is to focus on areas that will be of greatest benefit to developing nations where they feel that access to most vaccines is very poor at the same time keeping in mind that human health and the environment are protected.

The first product, possibly grown in maize, is likely to be an antibody that can be used to block HIV transmission and it has been decided to incorporate it into a microbicidal cream that could be used in the vagina. The second product will probably to be a post-bite vaccine for rabies, which is still a significant killer in Africa and southeast Asia.

Researchers at Pharma –Planta say that the plants will be grown in pharmaceutical production units on dedicated land , isolated from food crops. Thirty-nine labs in 11 European countries will work together, with input from researchers in South Africa, where HIV/Aids is a major public health issue. Scientific co-ordinators at Pharma –Planta say many commercial companies have withdrawn from vaccine development and production because of low economic returns ,however they say that Pharma-Planta hopes the technology it will develop over the course of its initial five years of funding will eventually boost the global supply of treatments.

Current methods used include genetic modification of human cells and microorganisms such as bacteria. These techniques are labour intensive, expensive and often only produce relatively small amounts of pharmaceuticals. Researchers at Pharma – Planta say that plants are inexpensive to grow as well as to engineer them to contain a gene for a pharmaceutical product and most importantly they could produce large quantities of drugs or vaccines at low cost. The project has yet to decide which plants to use but some of the plants mos
'"/>




Page: 1 2

Related medicine news :

1. A New study Throws Light On The Growth & Functions Of Insulin Producing Beta Cells
2. New Technique Developed By Scientists For Producing Stem Cells without Damaging Embryos
3. Producing More Drugs For Lethal Diseases Is Not The Answer
4. A Combined Research for Producing Chlamydia Vaccine Begins
5. Height of Liberation – Lesbians, No Less in Producing Babies (read Daughters
6. Understanding Chronic Infections May Help in Developing Therapeutic Vaccines
7. New Anthrax Vaccines Will Take time
8. Success Of Preventable High-Risk HPV Infections With Vaccines May Vary
9. Health and Human Services stockpiles 20 million bird flu Vaccines
10. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
11. Oral Edible vaccine for Allergy Vaccines

Post Your Comments:
(Date:11/27/2009)...ufacturers who use medical load cells at the heart...by bringing in technology partner Flintec early in...ive medical manufacturers are calling in Flintec l...jects, ensuring that progress will not be constrai...tdated technology. , (PRW...
(Date:11/26/2009)...PRNewswire/ -- The diabetes population in the Unit...s and annual medical spending on the disease is pr...today, according to a study published in the Decem...ing Diabetes ® Program (NCDP), a program of N...rom the University of Chicago. ,, According to ...
(Date:11/26/2009)...lead to strains or worse , , THURSDAY, N...ong with stuffing your turkey full to bursting, bu...r suitcase as you pack for holiday trips. , Mor...hospital emergency rooms, doctors, offices, clinic... injuries, such as muscle strains, pulls and tears...
(Date:11/26/2009)...of the Live Life Again Center, a practice offering...ing number of physicians who are taking advantage...h individuals who are interested in surgical weigh...is utilizing Facebook to share before-and-after ph...ommunity. , Dallas, TX (V...
(Date:11/26/2009)...nis, P.A. is offering free nationwide confidential...ontrol pills who have suffered a Deep Vein Thrombo...k or other related cardiac issues or had their Gal...0-856-6405 or go to the firm’s website at h...e evaluation form. , (PRW...
Breaking Medicine News(10 mins):Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3
... blood pressure under 70 mm Hg coupled with an ele...isk of heart attack and stroke than indicated by t... to a UC Irvine study. , Dr. Stanley Franklin and...ta from 9,657 participants in the Framingham Heart...
...Y 08 and Record Quarterly Operating Income , , HO... today announced results for the quarter ended Jan...ults for the third quarter of fiscal 2009 compared...nslations reducing third quarter sales by an estim...
... new study,s finding, , , WEDNESDAY, Feb. ...cked heart arteries, bypass surgery produced bette...f a stent, and thus "remains the standard of care"... who wrote an accompanying editorial. , The benefi...
...he Westaim Corporation announced today that for th...loss of $10.2 million, or 11 cents per share, on r... $58.0 million, or 62 cents per share, on revenues...share, compared to a net loss of $26.8 million, or...
...lent than full-blown stroke in people under 65, MR...thDay News) -- "Silent strokes" rarely produce sym...st five times more common than full-blown strokes ...f Medicine as a part of the ongoing Framingham Hea...
... Journal of the American Medical,Association ( J... Bioinformatics at the National Institute of Stati...h Columbia, highlight the statistical limitations ...tudy, published in JAMA (September 16, 2008) by ...
Other Medicine News:Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 2Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 3Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 4Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 5Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 6Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 7Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 8Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 9Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 10Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 11Health News:Is Bypass Truly Better than Stenting? 2Health News:Is Bypass Truly Better than Stenting? 3Health News:Westaim announces 2008 year-end results 2Health News:Westaim announces 2008 year-end results 3Health News:Westaim announces 2008 year-end results 4Health News:Westaim announces 2008 year-end results 5Health News:Westaim announces 2008 year-end results 6Health News:Westaim announces 2008 year-end results 7Health News:Westaim announces 2008 year-end results 8Health News:Westaim announces 2008 year-end results 9Health News:Westaim announces 2008 year-end results 10Health News:Westaim announces 2008 year-end results 11Health News:Westaim announces 2008 year-end results 12Health News:Silent Strokes More Common in Younger People Than Thought 2Health News:Silent Strokes More Common in Younger People Than Thought 3
(Date:11/25/2009)... Nov. 25 Reportlinker.com announce...n its catalogue: ,, Mammography Equipment - A...ortlinker.com/p0164330/Mammography-Equipment---A-G...nce of breast cancer in industrialized as well as ...ng growth in the mammography market. Globally, esc...
(Date:11/25/2009)..., N.C., Nov. 25 Cempra Pharmaceuti...es, president and chief executive officer, will pr... Conference at 8:50 a.m. EST, December 1, 2009, at...Fernandes will provide an overview of the company,... treatment of drug-resistant pathogens including M...
(Date:11/25/2009)...alif., Nov. 25 ChemoCentryx, Inc... from the Company,s PROTECT-1 (the Prospective Ran... Trial) of Traficet-EN(TM) (CCX282-B) in patients ...ed clinical efficacy with a favorable safety and t...nce of clinical efficacy in the reduction of disea...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Long Term Care Consumer Voices Strengthened 58768 1Long Term Care Consumer Voices Strengthened 58768 2Yongye International Announces 2010 2012 Strategic Plan 14335 1Yongye International Announces 2010 2012 Strategic Plan 14335 2Yongye International Announces 2010 2012 Strategic Plan 14335 3Yongye International Announces 2010 2012 Strategic Plan 14335 4Yongye International Announces 2010 2012 Strategic Plan 14335 5Face Masks Offer Protection Against Spreading H1N1 5187 1Face Masks Offer Protection Against Spreading H1N1 5187 2
... 3 Sangamo BioSciences, Inc.,(Nasdaq: SGMO ) an... milestones,achieved in 2008 and preview objective...Briefing to be held in New York City today. , Da...poration,s Research,Biotech Business Unit will dis...o companies, collaboration to commercialize zinc f...
...f., Dec. 3 Isis Pharmaceuticals,Inc. (Nasdaq: I...ls, Inc.,provided positive survival results from a...ombination with docetaxel and prednisone ("the OGX...one ("the control arm") for first-line,treatment o...The current 10.6,month median overall survival adv...
Other Medicine Technology:Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 2Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 4Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 5Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 6Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4
MIS Distal Femoral Alignment/Saw Guide and Intramedullary Rod
Ascent Anterior Referencing Femoral Instrument Case
Ascent Knee System Case # 2
Lineage Acetabular Cup System (Ceramic)
Medicine Products: